News

Molecular Forecaster Inc. (MFI) and TransBIOTech are pleased to announce a strategic partnership leveraging the complementary strengths of both organizations to develop drug discovery programs that combine MFI's customized Computer-Aided Drug Design (CADD) solutions with TransBIOTech's in vitro and in vivo expertise.

This multi-year funding aims to advance promising cancer therapies by conducting preclinical toxicity and efficacy studies required for regulatory approvals for clinical trials.

Feldan thanks its collaborators from the University of Iowa, University of Davis, Johns Hopkins University School of Medicine, Harvard University, Integrated DNA Technologies, and TransBIOTech for this achievement.